Platinum-based combination therapy (PCT) and outcomes for patients (pts) with mixed hepatocellular carcinoma and intrahepatic cholangiocarcinoma (mHCC/ICC).

Connell, Louise C.; Harding, James J.; Lowery, Maeve A.; Kemeny, Nancy E.; Cercek, Andrea; Abdelgawad, Marwa I; O'Reilly, Eileen Mary; Saltz, Leonard; Abou‐Alfa, Ghassan K.

doi:10.1200/jco.2015.33.15_suppl.e15146

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor biomarker levels before and after showed a 60% median reduction (range 13-80%). According to RECIST, a partial response was observed in 60%, while 40% had a stable disease, compared to 100% using RECIST V1.1 [92]. The study shows that radioembolization may be a promising method for treating patients who are not initial candidates for resection (Figure 5A-H).…”

Section: Transarterial Radioembolizationmentioning

confidence: 87%

See 1 more Smart Citation

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma

Renzulli

Ramai

Singh

et al. 2021

Cancers

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a primary and aggressive cancer of the biliary tree. Combined hepatocellular cholangiocarcinoma (CHC) is a distinctive primary liver malignancy which has properties of both hepatocytic and cholangiocytic differentiation. CHC appears to have a worse prognosis compared to hepatocellular carcinoma, and similar to that of intrahepatic CCA. While significant advances have been made in understanding the pathophysiology and treatment of these two tumor types, their prognosis remains poor. Currently, liver resection is the primary treatment modality; however, only a minority of patients are eligible for surgery. However, the use of locoregional therapies proves an alternative approach to treating locally advanced disease with the aim of converting to resectability or even transplantation. Locoregional therapies such as transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT), radiofrequency ablation (RFA), and photodynamic therapy (PDT) can provide patients with tumor control and increase the chances of survival. In this review, we appraise the evidence surrounding the use of locoregional therapies in treating patients with CCA and CHC.

show abstract

Section: Transarterial Radioembolizationmentioning

confidence: 87%

“…The study shows that radioembolization may be a promising method for treating patients who are not initial candidates for resection (Figure 5A-H). Furthermore, radioembolization may be an option for patients with metastatic disease, though with a lower response rate [91,92]. A-C).…”

Section: Transarterial Radioembolizationmentioning

confidence: 99%

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma

Renzulli

Ramai

Singh

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Because no specific evidence-based treatment for cHCC-iCCA has been established [130,131], advanced cHCC-iCCA is often treated similar to HCC or, more often, as iCCA [5,[132][133][134][135]. Rogers et al have reported a clinical benefit in 3 cases of patients with unresectable cHCC-iCCA treated with gemcitabine (gem)-platinum with or without bevacizumab (bev) [136] (Table 3).…”

Section: Systemic Treatmentmentioning

confidence: 99%

Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management

Schneider¹,

Khaled²,

Schirmacher³

et al. 2023

Liver Cancer

View full text Add to dashboard Cite

Background Combined hepatocellular-cholangiocarcinoma (cHCC-iCCA) is a rare type of primary liver cancer displaying characteristics of both hepatocytic and cholangiocytic differentiation. Summary Because of its aggressive nature, patients with cHCC-iCCA exhibit a poorer prognosis than those with HCC. Surgical resection and liver transplantation may be considered as curative treatment approaches; however, only a minority of patients are eligible at the time of diagnosis and postoperative recurrence rates are high. For cases that are not eligible for surgery, locoregional and systemic therapy are often administered based on treatment protocols applied for HCC or iCCA. Owing to the rarity of this cancer, there are still no established standard treatment protocols; therefore, the choice of therapy is often personalized and guided by the suspected predominant component. Further, the genomic and molecular heterogeneity of cHCC-iCCA can severely compromise the efficacy of the available therapies. Key Messages In the present review, we summarize the latest advances in cHCC-iCCA and attempt to clarify its terminology and molecular biology. We provide an overview of the etiology of cHCC-iCCA and present new insights into the molecular pathology of this disease that could contribute to further studies aiming to improve the patient outcomes through new systemic therapies.

show abstract